REFERENCES
1. National Center for Health Statistics. National health interview survey. Available from:https://www.cdc.gov/nchs/nhis/[Last accessed on 14 Jun 2024].
2. Gupta A, Wang Y, Spertus JA, et al. Trends in acute myocardial infarction in young patients and differences by sex and race, 2001 to 2010. J Am Coll Cardiol 2014;64:337-45.
3. Benjamin EJ, Muntner P, Alonso A, et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2019 update: a report from the american heart association. Circulation 2019;139:e56-e528.
4. Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO. Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.S. Obesity 2007;15:511-21.
5. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9.
6. Hirode G, Wong RJ. Trends in the prevalence of metabolic syndrome in the United States, 2011-2016. JAMA 2020;323:2526-8.
7. Aggarwal NR, Patel HN, Mehta LS, et al. Sex differences in ischemic heart disease: advances, obstacles, and next steps. Circ Cardiovasc Qual Outcomes 2018;11:e004437.
8. Peh ZH, Dihoum A, Hutton D, et al. Inflammation as a therapeutic target in heart failure with preserved ejection fraction. Front Cardiovasc Med 2023;10:1125687.
9. Schiattarella GG, Rodolico D, Hill JA. Metabolic inflammation in heart failure with preserved ejection fraction. Cardiovasc Res 2021;117:423-34.
10. Powell-Wiley TM, Poirier P, Burke LE, et al. American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and cardiovascular disease: a scientific statement from the american heart association. Circulation 2021;143:e984-e1010.
11. Lopez-Jimenez F, Almahmeed W, Bays H, et al. Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the world heart federation and world obesity federation. Eur J Prev Cardiol 2022;29:2218-37.
12. Kyle TK, Dhurandhar EJ, Allison DB. Regarding obesity as a disease: evolving policies and their implications. Endocrinol Metab Clin North Am 2016;45:511-20.
13. Lavie CJ, McAuley PA, Church TS, Milani RV, Blair SN. Obesity and cardiovascular diseases: implications regarding fitness, fatness, and severity in the obesity paradox. J Am Coll Cardiol 2014;63:1345-54.
14. Mahabadi AA, Massaro JM, Rosito GA, et al. Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the framingham heart study. Eur Heart J 2009;30:850-6.
15. Félix-Redondo FJ, Grau M, Baena-Díez JM, et al. Prevalence of obesity and associated cardiovascular risk: the DARIOS study. BMC Public Health 2013;13:542.
16. Ross R, Neeland IJ, Yamashita S, et al. Waist circumference as a vital sign in clinical practice: a consensus statement from the IAS and ICCR working group on visceral obesity. Nat Rev Endocrinol 2020;16:177-89.
17. Zhang C, Rexrode KM, van Dam RM, Li TY, Hu FB. Abdominal obesity and the risk of all-cause, cardiovascular, and cancer mortality: sixteen years of follow-up in US women. Circulation 2008;117:1658-67.
18. Peters SAE, Bots SH, Woodward M. Sex Differences in the association between measures of general and central adiposity and the risk of myocardial infarction: results from the UK biobank. J Am Heart Assoc 2018:7.
19. Oikonomou EK, Antoniades C. The role of adipose tissue in cardiovascular health and disease. Nat Rev Cardiol 2019;16:83-99.
20. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity, kidney dysfunction and hypertension: mechanistic links. Nat Rev Nephrol 2019;15:367-85.
21. Iliescu R, Tudorancea I, Irwin ED, Lohmeier TE. Chronic baroreflex activation restores spontaneous baroreflex control and variability of heart rate in obesity-induced hypertension. Am J Physiol Heart Circ Physiol 2013;305:H1080-8.
22. Mansukhani MP, Kara T, Caples SM, Somers VK. Chemoreflexes, sleep apnea, and sympathetic dysregulation. Curr Hypertens Rep 2014;16:476.
23. Machleidt F, Simon P, Krapalis AF, Hallschmid M, Lehnert H, Sayk F. Experimental hyperleptinemia acutely increases vasoconstrictory sympathetic nerve activity in healthy humans. J Clin Endocrinol Metab 2013;98:E491-6.
25. Liu J, Fox CS, Hickson DA, et al. Impact of abdominal visceral and subcutaneous adipose tissue on cardiometabolic risk factors: the Jackson heart study. J Clin Endocrinol Metab 2010;95:5419-26.
26. Aydin Ö, Nieuwdorp M, Gerdes V. The gut microbiome as a target for the treatment of type 2 diabetes. Curr Diab Rep 2018;18:55.
27. Heuvelman VD, Van Raalte DH, Smits MM. Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes. Cardiovasc Res 2020;116:916-30.
28. Caron A, Richard D. Neuronal systems and circuits involved in the control of food intake and adaptive thermogenesis. Ann N Y Acad Sci 2017;1391:35-53.
29. Gaur A, Pal GK, Ananthanarayanan PH, Pal P. Role of Ventromedial hypothalamus in high fat diet induced obesity in male rats: association with lipid profile, thyroid profile and insulin resistance. Ann Neurosci 2014;21:104-7.
30. Dube MG, Xu B, Kalra PS, Sninsky CA, Kalra SP. Disruption in neuropeptide Y and leptin signaling in obese ventromedial hypothalamic-lesioned rats. Brain Res 1999;816:38-46.
31. Kim AY, Shim JH, Choi HJ, Baek HM. Comparison of volumetric and shape changes of subcortical structures based on 3-dimensional image between obesity and normal-weighted subjects using 3.0 T MRI. J Clin Neurosci 2020;73:280-7.
32. Xu Y, Nedungadi TP, Zhu L, et al. Distinct hypothalamic neurons mediate estrogenic effects on energy homeostasis and reproduction. Cell Metab 2011;14:453-65.
33. Ezzat-Zadeh Z, Kim JS, Chase PB, Arjmandi BH. The cooccurrence of obesity, osteoporosis, and sarcopenia in the ovariectomized rat: a study for modeling osteosarcopenic obesity in rodents. J Aging Res 2017;2017:1454103.
34. El Khoudary SR, Aggarwal B, Beckie TM, et al; American Heart Association Prevention Science Committee of the Council on Epidemiology and Prevention. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the american heart association. Circulation 2020;142:e506-32.
35. Rajendran A, Minhas AS, Kazzi B, et al. Sex-specific differences in cardiovascular risk factors and implications for cardiovascular disease prevention in women. Atherosclerosis 2023;384:117269.
36. Manfrini O, Yoon J, van der Schaar M, et al. Sex differences in modifiable risk factors and severity of coronary artery disease. J Am Heart Assoc 2020;9:e017235.
37. Wang Y, O'Neil A, Jiao Y, et al. Sex differences in the association between diabetes and risk of cardiovascular disease, cancer, and all-cause and cause-specific mortality: a systematic review and meta-analysis of 5,162,654 participants. BMC Med 2019;17:136.
38. Madonna R, Balistreri CR, De Rosa S, et al. Impact of sex differences and diabetes on coronary atherosclerosis and ischemic heart disease. J Clin Med 2019;8:98.
39. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991;151:1141-7.
40. Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The rancho bernardo study. JAMA 1991;265:627-31.
41. Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr Rev 2016;37:278-316.
42. Hevener AL, Drew BG. The impact of estrogen receptor α expression in the pathogenesis of the metabolic syndrome. In: Spangenburg EE, editor. Integrative Biology of Women’s Health. New York: Springer; 2013. pp. 87-121.
43. Fatma J, Karoli R, Siddiqui Z, Gupta HP, Chandra A, Pandey M. Cardio-metabolic risk profile in women with previous history of pre-eclampsia. J Assoc Physicians India 2017;65:23-7.
44. Heidema WM, Scholten RR, Lotgering FK, Spaanderman ME. History of preeclampsia is more predictive of cardiometabolic and cardiovascular risk factors than obesity. Eur J Obstet Gynecol Reprod Biol 2015;194:189-93.
45. Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 2009;373:1773-9.
46. Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis. Diabetologia 2019;62:905-914.
47. Yu Y, Soohoo M, Sørensen HT, Li J, Arah OA. Gestational diabetes mellitus and the risks of overall and type-specific cardiovascular diseases: a population- and sibling-matched cohort study. Diabetes Care 2022;45:151-9.
48. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010;16:347-63.
49. Kakoly NS, Khomami MB, Joham AE, et al. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression. Hum Reprod Update 2018;24:455-67.
50. Osibogun O, Ogunmoroti O, Michos ED. Polycystic ovary syndrome and cardiometabolic risk: opportunities for cardiovascular disease prevention. Trends Cardiovasc Med 2020;30:399-404.
51. Oliver-Williams C, Vassard D, Pinborg A, Schmidt L. Risk of cardiovascular disease for women with polycystic ovary syndrome: results from a national Danish registry cohort study. Eur J Prev Cardiol 2021;28:e39-41.
52. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020;73:202-9.
53. Lonardo A, Singal AK, Osna N, Kharbanda KK. Effect of cofactors on NAFLD/NASH and MAFLD. A paradigm illustrating the pathomechanics of organ dysfunction. Metab Target Organ Damage 2022;2:12.
54. Wu S, Li Y, Zhang Y, et al. Sex and age differences in the association between metabolic dysfunction-associated fatty liver disease and heart failure: a prospective cohort study. Circ Heart Fail 2024;17:e010841.
55. Sousa P, Machado MV. MAFLD under the lens: the role of gut microbiota. Metab Target Organ Damage 2022;2:14.
57. Libby P, Hansson GK. From focal lipid storage to systemic inflammation: JACC review topic of the week. J Am Coll Cardiol 2019;74:1594-607.
58. Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol 2011;31:969-79.
59. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur Heart J 2017;38:2459-72.
61. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007;117:175-84.
62. Wu ZJ, Cheng YJ, Gu WJ, Aung LH. Adiponectin is associated with increased mortality in patients with already established cardiovascular disease: a systematic review and meta-analysis. Metabolism 2014;63:1157-66.
63. Lee S, Kwak HB. Role of adiponectin in metabolic and cardiovascular disease. J Exerc Rehabil 2014;10:54-9.
64. Fuente-Martín E, Argente-Arizón P, Ros P, Argente J, Chowen JA. Sex differences in adipose tissue: it is not only a question of quantity and distribution. Adipocyte 2013;2:128-34.
65. Moran CA, Collins LF, Beydoun N, et al. Cardiovascular implications of immune disorders in women. Circ Res 2022;130:593-610.
66. Nelson MD, Wei J, Bairey Merz CN. Coronary microvascular dysfunction and heart failure with preserved ejection fraction as female-pattern cardiovascular disease: the chicken or the egg? Eur Heart J 2018;39:850-2.
69. Ter Horst R, van den Munckhof ICL, Schraa K, et al. Sex-specific regulation of inflammation and metabolic syndrome in obesity. Arterioscler Thromb Vasc Biol 2020;40:1787-800.
70. Ndumele CE, Rangaswami J, Chow SL, et al. American Heart Association. Cardiovascular-kidney-metabolic health: a presidential advisory from the American heart association. Circulation 2023;148:1606-35.
71. Bairey Merz CN, Pepine CJ, Walsh MN, Fleg JL. Ischemia and no obstructive coronary artery disease (INOCA): developing evidence-based therapies and research agenda for the next decade. Circulation 2017;135:1075-92.
72. Anand SS, Islam S, Rosengren A, et al. INTERHEART Investigators. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J 2008;29:932-40.
73. Benjamin EJ, Virani SS, Callaway CW, et al. American Heart Association Council on epidemiology and prevention statistics committee and stroke statistics subcommittee. Heart disease and stroke statistics-2018 update: a report from the american heart association. Circulation 2018;137:e67-e492.
74. Bagi Z, Broskova Z, Feher A. Obesity and coronary microvascular disease - implications for adipose tissue-mediated remote inflammatory response. Curr Vasc Pharmacol 2014;12:453-61.
75. Sara JD, Taher R, Kolluri N, Vella A, Lerman LO, Lerman A. Coronary microvascular dysfunction is associated with poor glycemic control amongst female diabetics with chest pain and non-obstructive coronary artery disease. Cardiovasc Diabetol 2019;18:22.
76. Das SR, Alexander KP, Chen AY, et al. Impact of body weight and extreme obesity on the presentation, treatment, and in-hospital outcomes of 50,149 patients with ST-Segment elevation myocardial infarction results from the NCDR (National Cardiovascular Data Registry). J Am Coll Cardiol 2011;58:2642-50.
77. Cho JH, Kim HL, Kim MA, et al. Association between obesity type and obstructive coronary artery disease in stable symptomatic postmenopausal women: data from the KoRean wOmen'S chest pain rEgistry (KoROSE). Menopause 2019;26:1272-6.
78. Kulie T, Slattengren A, Redmer J, Counts H, Eglash A, Schrager S. Obesity and women's health: an evidence-based review. J Am Board Fam Med 2011;24:75-85.
79. Katta N, Loethen T, Lavie CJ, Alpert MA. Obesity and coronary heart disease: epidemiology, pathology, and coronary artery imaging. Curr Probl Cardiol 2021;46:100655.
80. Maggio CA, Pi-Sunyer FX. Obesity and type 2 diabetes. Endocrinol Metab Clin North Am 2003;32:805-22, viii.
81. Donahue RP, Goldberg RJ, Chen Z, Gore JM, Alpert JS. The influence of sex and diabetes mellitus on survival following acute myocardial infarction: a community-wide perspective. J Clin Epidemiol 1993;46:245-52.
82. Abbott RD. The impact of diabetes on survival following myocardial infarction in men vs women: the Framingham study. JAMA 1988;260:3456.
83. Gajardo-Navarrete J, Ibieta G, Concha M, et al. [Coronary artery disease in pre and postmenopausal women. The influence of type 2 diabetes mellitus]. Rev Med Chil 2020;148:145-50.
84. Juutilainen A, Kortelainen S, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Gender difference in the impact of type 2 diabetes on coronary heart disease risk. Diabetes Care 2004;27:2898-904.
85. Shimokawa H, Suda A, Takahashi J, et al. Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the coronary vasomotor disorders international study (COVADIS) group. Eur Heart J 2021;42:4592-600.
86. Bajaj NS, Osborne MT, Gupta A, et al. Coronary microvascular dysfunction and cardiovascular risk in obese patients. J Am Coll Cardiol 2018;72:707-17.
88. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the american college of cardiology/American heart association task force on clinical practice guidelines. Circulation 2019;140:e596-646.
89. Wexler DJ, Grant RW, Meigs JB, Nathan DM, Cagliero E. Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care 2005;28:514-20.
90. Abuful A, Gidron Y, Henkin Y. Physicians' attitudes toward preventive therapy for coronary artery disease: is there a gender bias? Clin Cardiol 2005;28:389-93.
91. Bairey Merz CN, Andersen H, Sprague E, et al. Knowledge, attitudes, and beliefs regarding cardiovascular disease in women: the women's heart alliance. J Am Coll Cardiol 2017;70:123-32.
92. Savji N, Meijers WC, Bartz TM, et al. The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF. JACC Heart Fail 2018;6:701-9.
93. Upadhya B, Kitzman DW. Heart failure with preserved ejection fraction: New approaches to diagnosis and management. Clin Cardiol 2020;43:145-55.
94. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002;347:305-13.
95. von Bibra H, Paulus W, St John Sutton W, et al. Cardiometabolic syndrome and increased risk of heart failure. Curr Heart Fail Rep 2016;13:219-29.
97. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013;62:263-71.
98. Packer M, Lam CSP, Lund LH, Maurer MS, Borlaug BA. Characterization of the inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease. Eur J Heart Fail 2020;22:1551-67.
99. Zeller CB, Appenzeller S. Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors. Curr Cardiol Rev 2008;4:116-22.
100. Mehta PK, Levit RD, Wood MJ, et al. American College of Cardiology Cardiovascular Disease in Women Committee. Chronic rheumatologic disorders and cardiovascular disease risk in women. Am Heart J Plus 2023;27:100267.
101. Sirichand S, Killu AM, Padmanabhan D, et al. Incidence of Idiopathic ventricular arrhythmias: a population-based study. Circ Arrhythm Electrophysiol 2017:10.
102. Ko D, Rahman F, Schnabel RB, Yin X, Benjamin EJ, Christophersen IE. Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis. Nat Rev Cardiol 2016;13:321-32.
103. Huxley RR, Lopez FL, Folsom AR, et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the atherosclerosis risk in communities (ARIC) study. Circulation 2011;123:1501-8.
104. Tedrow UB, Conen D, Ridker PM, et al. The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (women's health study). J Am Coll Cardiol 2010;55:2319-27.
105. Pietrasik G, Goldenberg I, McNitt S, Moss AJ, Zareba W. Obesity as a risk factor for sustained ventricular tachyarrhythmias in MADIT II patients. J Cardiovasc Electrophysiol 2007;18:181-4.
106. Aune D, Schlesinger S, Norat T, Riboli E. Body mass index, abdominal fatness, and the risk of sudden cardiac death: a systematic review and dose-response meta-analysis of prospective studies. Eur J Epidemiol 2018;33:711-22.
107. Chi PC, Chang SC, Yun CH, et al. The associations between various ectopic visceral adiposity and body surface electrocardiographic alterations: potential differences between local and remote systemic effects. PLoS One 2016;11:e0158300.
108. Patel KHK, Hwang T, Se Liebers C, Ng FS. Epicardial adipose tissue as a mediator of cardiac arrhythmias. Am J Physiol Heart Circ Physiol 2022;322:H129-44.
109. Omran J, Firwana B, Koerber S, Bostick B, Alpert MA. Effect of obesity and weight loss on ventricular repolarization: a systematic review and meta-analysis. Obes Rev 2016;17:520-30.
110. Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004;292:2471-7.
111. Benjamin EJ. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham heart study. JAMA 1994;271:840.
112. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation 2019;140:e125-51.
113. Hindricks G, Potpara T, Dagres N, et al. ESC Scientific Document Group. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the european association for cardio-thoracic surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European society of cardiology (ESC) developed with the special contribution of the European heart rhythm association (EHRA) of the ESC. Eur Heart J 2021;42:373-498.
114. Donnellan E, Wazni O, Kanj M, et al. Outcomes of atrial fibrillation ablation in morbidly obese patients following bariatric surgery compared with a nonobese cohort. Circ Arrhythm Electrophysiol 2019;12:e007598.
115. Chang SH, Wu LS, Chiou MJ, et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol 2014;13:123.
116. Abumuamar AM, Newman D, Dorian P, Shapiro CM. Cardiac effects of CPAP treatment in patients with obstructive sleep apnea and atrial fibrillation. J Interv Card Electrophysiol 2019;54:289-97.
117. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999;100:376-80.
118. Albert MA, Glynn RJ, Buring J, Ridker PM. Impact of traditional and novel risk factors on the relationship between socioeconomic status and incident cardiovascular events. Circulation 2006;114:2619-26.
119. Vaccarino V, Shah AJ, Mehta PK, et al. Brain-heart connections in stress and cardiovascular disease: implications for the cardiac patient. Atherosclerosis 2021;328:74-82.
120. Mehta PK, Sharma A, Bremner JD, Vaccarino V. Mental stress-induced myocardial ischemia. Curr Cardiol Rep 2022;24:2109-20.
121. Mulle JG, Vaccarino V. Cardiovascular disease, psychosocial factors, and genetics: the case of depression. Prog Cardiovasc Dis 2013;55:557-62.
122. Vaccarino V, Johnson BD, Sheps DS, et al. National Heart, Lung, and Blood Institute. Depression, inflammation, and incident cardiovascular disease in women with suspected coronary ischemia: the national heart, lung, and blood institute-sponsored WISE study. J Am Coll Cardiol 2007;50:2044-50.
123. Mehta PK, Thobani A, Vaccarino V. Coronary artery spasm, coronary reactivity, and their psychological context. Psychosom Med 2019;81:233-6.
124. Vaccarino V, Almuwaqqat Z, Kim JH, et al. Association of mental stress-induced myocardial ischemia with cardiovascular events in patients with coronary heart disease. JAMA 2021;326:1818-28.
125. Sullivan S, Hammadah M, Al Mheid I, et al. Sex differences in hemodynamic and microvascular mechanisms of myocardial ischemia induced by mental stress. Arterioscler Thromb Vasc Biol 2018;38:473-80.
126. Rajan S, McKee M, Rangarajan S, et al. Prospective Urban Rural Epidemiology (PURE) Study Investigators. Association of symptoms of depression with cardiovascular disease and mortality in low-, middle-, and high-income countries. JAMA Psychiatry 2020;77:1052-63.
127. Salk RH, Hyde JS, Abramson LY. Gender differences in depression in representative national samples: meta-analyses of diagnoses and symptoms. Psychol Bull 2017;143:783-822.
128. Thombs BD, Bass EB, Ford DE, et al. Prevalence of depression in survivors of acute myocardial infarction. J Gen Intern Med 2006;21:30-8.
129. Smolderen KG, Buchanan DM, Gosch K, et al. Depression treatment and 1-year mortality after acute myocardial infarction: insights from the TRIUMPH registry (translational research investigating underlying disparities in acute myocardial infarction patients' health status). Circulation 2017;135:1681-9.
130. Lichtman JH, Bigger JT Jr, Blumenthal JA, et al. American Heart Association Prevention Committee of the Council on Cardiovascular Nursing; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention; American Heart Association Interdisciplinary Council on Quality of Care and Outcomes Research; American Psychiatric Association. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American heart association prevention committee of the council on cardiovascular nursing, council on clinical cardiology, council on epidemiology and prevention, and interdisciplinary council on quality of care and outcomes research: endorsed by the American psychiatric association. Circulation 2008;118:1768-75.
131. Lau ES, Paniagua SM, Guseh JS, et al. Sex differences in circulating biomarkers of cardiovascular disease. J Am Coll Cardiol 2019;74:1543-53.
132. Maas AH, Franke HR. Women's health in menopause with a focus on hypertension. Neth Heart J 2009;17:68-72.
133. Wang D, Jackson EA, Karvonen-Gutierrez CA, et al. Healthy lifestyle during the midlife is prospectively associated with less subclinical carotid atherosclerosis: the study of women's health across the nation. J Am Heart Assoc 2018;7:e010405.
134. Janssen I, Powell LH, Crawford S, Lasley B, Sutton-Tyrrell K. Menopause and the metabolic syndrome: the study of women's health across the nation. Arch Intern Med 2008;168:1568-75.
135. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002;288:321-33.
136. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77.
137. Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2015;2015:CD002229.
138. Bergendal A, Kieler H, Sundström A, Hirschberg AL, Kocoska-Maras L. Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration. Menopause 2016;23:593-9.
139. Santen RJ, Mirkin S, Bernick B, Constantine GD. Systemic estradiol levels with low-dose vaginal estrogens. Menopause 2020;27:361-70.
140. Fihn SD, Gardin JM, Abrams J, et al. American College of Cardiology Foundation/American Heart Association Task Force. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American college of cardiology foundation/American heart association task force on practice guidelines, and the American college of physicians, American association for thoracic surgery, preventive cardiovascular nurses association, society for cardiovascular angiography and interventions, and society of thoracic surgeons. Circulation 2012;126:e354-471.
141. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American college of cardiology/American heart association task force on practice guidelines and the obesity society. Circulation 2014:129.
142. Christensen P, Meinert Larsen T, Westerterp-Plantenga M, et al. Men and women respond differently to rapid weight loss: metabolic outcomes of a multi-centre intervention study after a low-energy diet in 2500 overweight, individuals with pre-diabetes (PREVIEW). Diabetes Obes Metab 2018;20:2840-51.
143. Garvey WT, Mechanick JI, Brett EM, et al. Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract 2016;22 Suppl 3:1-203.
144. Wilding JPH, Batterham RL, Calanna S, et al. STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384:989-1002.
145. Pi-Sunyer X, Astrup A, Fujioka K, et al. SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11-22.
146. Marso SP, Daniels GH, Brown-Frandsen K, et al. LEADER Steering Committee; LEADER trial investigators. liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-22.
147. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-1844.
148. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389:2221-32.
149. Jastreboff AM, Aronne LJ, Ahmad NN, et al. SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:205-16.
150. Jensen MD, Ryan DH, Apovian CM, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American college of cardiology/American heart association task force on practice guidelines and the obesity society. J Am Coll Cardiol 2014;63:2985-3023.
151. van Veldhuisen SL, Gorter TM, van Woerden G, et al. Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J 2022;43:1955-69.
152. Doumouras AG, Lee Y, Paterson JM, et al. Association between bariatric surgery and major adverse diabetes outcomes in patients with diabetes and obesity. JAMA Netw Open 2021;4:e216820.
